NTRB
Nutriband Inc
NASDAQ · Pharmaceuticals
$4.35
+0.01 (+0.12%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.09M | 21.69M | 16.36M |
| Net Income | 2.64M | 2.61M | 1.89M |
| EPS | — | — | — |
| Profit Margin | 12.5% | 12.0% | 11.5% |
| Rev Growth | -6.9% | +19.5% | +23.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 20.64M | 24.66M | 23.39M |
| Total Equity | 35.59M | 37.36M | 36.10M |
| D/E Ratio | 0.58 | 0.66 | 0.65 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 4.33M | 4.63M | 3.66M |
| Free Cash Flow | 3.40M | 2.95M | 1.96M |